186 related articles for article (PubMed ID: 32085690)
1. Examining the evidence for PFO closure and novel oral anticoagulants for treatment of cryptogenic stroke.
Khan R
Expert Rev Cardiovasc Ther; 2020 Mar; 18(3):139-148. PubMed ID: 32085690
[No Abstract] [Full Text] [Related]
2. Patent foramen ovale transcatheter closure vs. medical therapy on recurrent vascular events: a systematic review and meta-analysis of randomized controlled trials.
Rengifo-Moreno P; Palacios IF; Junpaparp P; Witzke CF; Morris DL; Romero-Corral A
Eur Heart J; 2013 Nov; 34(43):3342-52. PubMed ID: 23847132
[TBL] [Abstract][Full Text] [Related]
3. Meta-analysis of Randomized Controlled Trials on Patent Foramen Ovale Closure Versus Medical Therapy for Secondary Prevention of Cryptogenic Stroke.
Smer A; Salih M; Mahfood Haddad T; Guddeti R; Saadi A; Saurav A; Belbase R; Ayan M; Traina M; Alla V; Del Core M
Am J Cardiol; 2018 Jun; 121(11):1393-1399. PubMed ID: 29680170
[TBL] [Abstract][Full Text] [Related]
4. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke.
Mas JL; Derumeaux G; Guillon B; Massardier E; Hosseini H; Mechtouff L; Arquizan C; Béjot Y; Vuillier F; Detante O; Guidoux C; Canaple S; Vaduva C; Dequatre-Ponchelle N; Sibon I; Garnier P; Ferrier A; Timsit S; Robinet-Borgomano E; Sablot D; Lacour JC; Zuber M; Favrole P; Pinel JF; Apoil M; Reiner P; Lefebvre C; Guérin P; Piot C; Rossi R; Dubois-Randé JL; Eicher JC; Meneveau N; Lusson JR; Bertrand B; Schleich JM; Godart F; Thambo JB; Leborgne L; Michel P; Pierard L; Turc G; Barthelet M; Charles-Nelson A; Weimar C; Moulin T; Juliard JM; Chatellier G;
N Engl J Med; 2017 Sep; 377(11):1011-1021. PubMed ID: 28902593
[TBL] [Abstract][Full Text] [Related]
5. Updated meta-analysis of closure of patent foramen ovale versus medical therapy after cryptogenic stroke.
Nasir UB; Qureshi WT; Jogu H; Wolfe E; Dutta A; Majeed CN; Tan WA
Cardiovasc Revasc Med; 2019 Mar; 20(3):187-193. PubMed ID: 30905408
[TBL] [Abstract][Full Text] [Related]
6. Dabigatran or Aspirin After Embolic Stroke of Undetermined Source in Patients With Patent Foramen Ovale: Results From RE-SPECT ESUS.
Diener HC; Chutinet A; Easton JD; Granger CB; Kleine E; Marquardt L; Meyerhoff J; Zini A; Sacco RL
Stroke; 2021 Mar; 52(3):1065-1068. PubMed ID: 33504190
[TBL] [Abstract][Full Text] [Related]
7. The Case for Selective Patent Foramen Ovale Closure After Cryptogenic Stroke.
Wiktor DM; Carroll JD
Circ Cardiovasc Interv; 2018 Mar; 11(3):e004152. PubMed ID: 29870380
[TBL] [Abstract][Full Text] [Related]
8. Closure, Anticoagulation, or Antiplatelet Therapy for Cryptogenic Stroke With Patent Foramen Ovale: Systematic Review of Randomized Trials, Sequential Meta-Analysis, and New Insights From the CLOSE Study.
Turc G; Calvet D; Guérin P; Sroussi M; Chatellier G; Mas JL;
J Am Heart Assoc; 2018 Jun; 7(12):. PubMed ID: 29910193
[TBL] [Abstract][Full Text] [Related]
9. close: Closure of patent foramen ovale, oral anticoagulants or antiplatelet therapy to prevent stroke recurrence: Study design.
Mas JL; Derumeaux G; Amarenco P; Arquizan C; Aubry P; Barthelet M; Bertrand B; Brochet E; Cabanes L; Donal E; Dubois-Randé JL; Durand-Zaleski I; Ernande L; Finet G; Fraisse A; Giroud M; Guérin P; Habib G; Juliard JM; Leys D; Lièvre M; Lusson JR; Marcon F; Michel P; Moulin T; Mounier-Vehier F; Pierard L; Piot C; Rey C; Rodier G; Roudaut R; Schleich JM; Teiger E; Turc G; Vuillier F; Weimar C; Woimant F; Chatellier G;
Int J Stroke; 2016 Aug; 11(6):724-32. PubMed ID: 27056964
[TBL] [Abstract][Full Text] [Related]
10. Recurrent Stroke Reduction with Patent Foramen Ovale Closure versus Medical Therapy Based on Patent Foramen Ovale Characteristics: A Meta-Analysis of Randomized Controlled Trials.
Garg A; Thawabi M; Rout A; Sossou C; Cohen M; Kostis JB
Cardiology; 2019; 144(1-2):40-49. PubMed ID: 31574522
[TBL] [Abstract][Full Text] [Related]
11. Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial.
Kasner SE; Swaminathan B; Lavados P; Sharma M; Muir K; Veltkamp R; Ameriso SF; Endres M; Lutsep H; Messé SR; Spence JD; Nedeltechev K; Perera K; Santo G; Olavarria V; Lindgren A; Bangdiwala S; Shoamanesh A; Berkowitz SD; Mundl H; Connolly SJ; Hart RG;
Lancet Neurol; 2018 Dec; 17(12):1053-1060. PubMed ID: 30274772
[TBL] [Abstract][Full Text] [Related]
12. Device closure of patent foramen ovale versus medical therapy in cryptogenic stroke: a systematic review and meta-analysis.
Khan AR; Bin Abdulhak AA; Sheikh MA; Khan S; Erwin PJ; Tleyjeh I; Khuder S; Eltahawy EA
JACC Cardiovasc Interv; 2013 Dec; 6(12):1316-23. PubMed ID: 24139929
[TBL] [Abstract][Full Text] [Related]
13. Interventional closure vs. medical therapy of patent foramen ovale for secondary prevention of stroke: updated meta-analysis.
Vukadinović D; Schirmer SH; Vukadinović AN; Ukena C; Scheller B; Mahfoud F; Böhm M
Clin Res Cardiol; 2019 Feb; 108(2):157-166. PubMed ID: 30051178
[TBL] [Abstract][Full Text] [Related]
14. Transcatheter Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke: A Meta-Analysis of Randomized Controlled Trials.
Darmoch F; Al-Khadra Y; Soud M; Fanari Z; Alraies MC
Cerebrovasc Dis; 2018; 45(3-4):162-169. PubMed ID: 29597192
[TBL] [Abstract][Full Text] [Related]
15. Is Patent Foramen Ovale Closure More Effective Than Medical Therapy in Preventing Stroke Recurrence in Patients With Cryptogenic Stroke?: A Critically Appraised Topic.
Valencia-Sanchez C; Fortuin FD; Sweeney JP; Ingall TJ; Marks LA; Wingerchuk DM; O'Carroll CB
Neurologist; 2018 Sep; 23(5):175-180. PubMed ID: 30169372
[TBL] [Abstract][Full Text] [Related]
16. Transcatheter Closure of Patent Foramen Ovale: Randomized Trial Update.
Arfaras-Melainis A; Palaiodimos L; Mojadidi MK
Interv Cardiol Clin; 2019 Oct; 8(4):341-356. PubMed ID: 31445719
[TBL] [Abstract][Full Text] [Related]
17. Patent Foramen Ovale Closure Versus Medical Therapy for Cryptogenic Stroke: Meta-Analysis of Randomised Trials.
Wang TKM; Wang MTM; Ruygrok P
Heart Lung Circ; 2019 Apr; 28(4):623-631. PubMed ID: 29602754
[TBL] [Abstract][Full Text] [Related]
18. Percutaneous closure of patent foramen ovale for cryptogenic stroke: a meta-analysis of randomized controlled trials.
Kwong JS; Lam YY; Yu CM
Int J Cardiol; 2013 Oct; 168(4):4132-8. PubMed ID: 23890879
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the cost-effectiveness of percutaneous closure of a patent foramen ovale versus medical management in patients with a cryptogenic stroke: from the UK payer perspective.
Hildick-Smith D; Turner M; Shaw L; Nakum M; Hartaigh BÓ; Evans RM; Rhodes JF; Sondergaard L; Kasner SE
J Med Econ; 2019 Feb; 22(2):131-139. PubMed ID: 30424680
[TBL] [Abstract][Full Text] [Related]
20. Patent foramen ovale (PFO) closure versus medical therapy for prevention of recurrent stroke in patients with prior cryptogenic stroke: A systematic review and meta-analysis of randomized controlled trials.
Akobeng AK; Abdelgadir I; Boudjemline Y; Hijazi ZM
Catheter Cardiovasc Interv; 2018 Jul; 92(1):165-173. PubMed ID: 29602258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
